Samsung Epis Holdings (0126Z0) Q2 2026 earnings summary

Executive summary

• Q2 2026 revenue and operating profit declined due to adjustments in product supply schedules, but profit margin was maintained at the prior-year level through efficient cost execution.

• H1 2026 revenue and operating profit grew 6% year-over-year, driven by milestone recognition in Q1.

• Operates as a holding company with three subsidiaries focused on biosimilars, next-gen bio platforms, and ADC technology, with the main revenue driver being biosimilar commercialization.

• 2026 half-year revenue reached KRW 845.8 billion, with 94.3% from biosimilar products and 5.7% from services.

• Major customers include Biogen (37.1% of sales), Organon (27.2%), and Sandoz (11.6%).

Financial highlights

• Q2 2026 consolidated revenue: 392B KRW; operating profit: 59B KRW (OPM: 22%).

• H1 2026 consolidated revenue: 846B KRW; operating profit: 149B KRW (OPM: 27%).

• Net profit for H1 2026: 185.3B KRW; Q2 net profit: 107B KRW.

• Gross margin: 53.5%; operating margin: 17.7%; net margin: 21.9%.

• Cash and cash equivalents: KRW 186.0 billion; total assets: KRW 8.0 trillion.

Outlook and guidance

• FY26 guidance maintained for over 10% annual revenue growth, supported by normalization of supply scheduling.

• Focus on expanding biosimilar portfolio and global market share, with continued investment in ADC and obesity drug pipelines.

• Plans to leverage partnerships for commercialization and R&D.